Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

Publisher： Karger

E-ISSN： 1423-0151|20|4|332-335

ISSN： 1011-7571

Source： Medical Principles and Practice, Vol.20, Iss.4, 2011-05, pp. : 332-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism

By Erem Cihangir

Endocrine Journal, Vol. 35, Iss. 1, 2009-02 ,pp. : 75-80

Humana Press, Inc

Access to resources Recommend Favorite

Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation

By Watanabe R. Wada H. Watanabe Y. Sakakura M. Nakasaki T. Mori Y. Nishikawa M. Gabazza E.C. Nobori T. Shiku H.

Thrombosis Research, Vol. 104, Iss. 1, 2001-10 ,pp. : 1-6

Elsevier

Access to resources Recommend Favorite

Patients on Peritoneal Dialysis But Not on Hemodialysis Have Elevated Concentration and Activity of Thrombin-Activatable Fibrinolysis Inhibitor

By Hryszko T. Malyszko J. Malyszko J.S. Brzosko S. Mysliwiec M.

Thrombosis Research, Vol. 104, Iss. 4, 2001-11 ,pp. : 233-238

Elsevier

Access to resources Recommend Favorite

Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

Cerebrovascular Diseases, Vol. 42, Iss. 5-6, 2016-07 ,pp. : 404-414

Karger

Access to resources Recommend Favorite

Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis

By Wang Xinkang Smith Patricia Hsu Mei-Yin Tamasi Joseph Bird Eileen Schumacher William

Journal of Thrombosis and Thrombolysis, Vol. 23, Iss. 1, 2007-02 ,pp. : 41-49

Springer Publishing Company

Access to resources Recommend Favorite